82,250 Shares in Day One Biopharmaceuticals, Inc. $DAWN Acquired by Perkins Capital Management Inc.

Perkins Capital Management Inc. purchased a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 82,250 shares of the company’s stock, valued at approximately $580,000. Perkins Capital Management Inc. owned about 0.08% of Day One Biopharmaceuticals as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of DAWN. Ameritas Investment Partners Inc. grew its stake in Day One Biopharmaceuticals by 44.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock valued at $48,000 after buying an additional 2,264 shares during the last quarter. Entropy Technologies LP bought a new stake in Day One Biopharmaceuticals during the second quarter valued at about $67,000. Prudential Financial Inc. bought a new stake in Day One Biopharmaceuticals during the second quarter valued at about $69,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Day One Biopharmaceuticals in the second quarter valued at about $76,000. Finally, Lazard Asset Management LLC bought a new position in shares of Day One Biopharmaceuticals in the second quarter worth about $89,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Stock Performance

NASDAQ:DAWN opened at $11.95 on Monday. The company has a 50-day moving average of $9.36 and a 200-day moving average of $8.00. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -7.86 and a beta of -1.27. Day One Biopharmaceuticals, Inc. has a 52 week low of $5.64 and a 52 week high of $13.53.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.09. The firm had revenue of $39.80 million for the quarter, compared to analysts’ expectations of $38.20 million. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The company’s quarterly revenue was down 57.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.38 earnings per share. Sell-side analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CFO Charles N. York II sold 4,062 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $8.91, for a total transaction of $36,192.42. Following the completion of the transaction, the chief financial officer directly owned 294,715 shares in the company, valued at approximately $2,625,910.65. The trade was a 1.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jeremy Bender sold 15,894 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $141,615.54. Following the completion of the sale, the chief executive officer owned 177,165 shares in the company, valued at approximately $1,578,540.15. This trade represents a 8.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 28,001 shares of company stock worth $249,489. 6.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

DAWN has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, November 24th. JPMorgan Chase & Co. increased their price objective on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Zacks Research upgraded shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. Finally, TD Cowen began coverage on shares of Day One Biopharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating and a $34.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.71.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.